IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer
October 30 2019 - 6:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage
biopharmaceutical company pioneering a novel class of
immunotherapies, today announced the appointment of Joanne
Schindler, M.D., D.V.M. as its new Chief Medical Officer, effective
November 4, 2019. Dr. Schindler will succeed Gabriela Rosu, M.D.,
who is leaving the company to pursue other opportunities.
“We are very excited to welcome Dr. Joanne Schindler, who brings
a wealth of experience in oncology-focused drug development and
clinical trial execution to IMV,” said Fred Ors, Chief Executive
Officer of IMV. “Over the last few years, our clinical efforts have
sought to leverage the potential of our DPX technology to deliver a
novel class of immunotherapies for the treatment of patients with
hard-to-treat cancers. We expect to benefit greatly from Joanne’s
leadership as we near key proof-of-concept readouts from our lead
program and as we continue to explore the breadth of our platform
across other targets of interest.”
Mr. Ors continued, “We also want to take this opportunity to
thank Dr. Gabriela Rosu for her many contributions to IMV’s
clinical program and wish her the best in her future pursuits.”
Dr. Schindler brings over 15 years of experience in the
biopharmaceutical industry, primarily in early-stage oncology drug
development. Most recently, she served as Vice President, Clinical
Development and Executive Medical Director at H3 Biomedicine,
overseeing the company’s clinical development efforts. Previously,
she worked as Vice President, Clinical Development at Constellation
Pharmaceuticals, and earlier held various clinical development
leadership roles at SynDevRx, ImmunoGen, Novartis, Fresenius
Biotech and GlycoGenesys. Over the course of her career, Dr.
Schindler has played an instrumental role in advancing novel
programs into the clinic, as well as the development and execution
of clinical strategy. She holds an M.D. from the University of
Connecticut School of Medicine, a D.V.M. from Tufts University
School of Veterinary Medicine and a B.A. in biology from Brandeis
University.
“I am delighted to join IMV at this critical stage in the
company’s growth,” said Dr. Schindler. “Immunotherapy is at the
forefront of novel treatments for cancer and I have been deeply
impressed with IMV’s sophisticated science and data produced to
date. Targeted T-cells born out of IMV’s DPX platform have
exhibited the potential to elicit a more rapid, robust and
sustained immune response over other therapies, particularly when
paired with a highly prevalent tumor-associated target like
survivin. I look forward to working with the team to advance its
clinical portfolio, to unlock the promise of this technology and to
bring these important benefits to cancer patients in need.”
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac as a monotherapy in advanced
ovarian cancer, as well as a combination therapy in multiple
clinical studies with Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory approvals. IMV
Inc. assumes no responsibility to update forward-looking statements
in this press release except as required by law. These
forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are
not limited to, our ability to access capital, the successful and
timely completion of clinical trials, the receipt of all regulatory
approvals and other risks detailed from time to time in our ongoing
quarterly filings and annual information form Investors are
cautioned not to rely on these forward-looking statements and are
encouraged to read IMV’s continuous disclosure documents, including
its current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191030005488/en/
Investor Relations
Marc Jasmin, Senior Director, Investor Relations, IMV O:
(902) 492-1819, ext: 1042 M: (514) 617-9481 E:
mjasmin@imv-inc.com
Josh Rappaport, Director, Stern IR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media
Mrs. Delphine Davan, Director of Communications, IMV M:
(514) 968-1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024